TICKERNERD
Menu
ADRXHealthcare · Biotechnology

ADRX Stock Forecast: ADARx Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$18
+0.73% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 0 of 100 as at 13 Oct 2026 — in the weakest quartile.

Market cap
$1.9B
Ticker Nerd rank
0 / 100
Median analyst target
—
Analysts covering
—
Total return, dividends reinvested
1W
+2.9%
From high
−13.6%
From low
+2.9%
$17
$21
Range since 25 Sept 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

ADRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores ADARx Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Oct 2026
0 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
36
Revisions
25
Issuance
10
Accruals
8
Growth
8
Value
4
Momentum
4
Quality
3
Volatility
1

Size (36): Smaller than most of the companies we track.

Volatility (1): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ADRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ADRX, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ADRX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ADRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

ADARx Pharmaceuticals, Inc. (ADRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
310.8×

Cheaper than 2% of US stocks

Price / book
—
EV / EBITDA
−17.5×

Cheaper than 89% of US stocks

Growth & margins
Revenue growth (YoY)
258.7%

Higher than 96% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−4006.8%

Higher than 3% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
—
Return on assets
—
Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

ADARx Pharmaceuticals, Inc. (ADRX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • ADARx Pharmaceuticals, Inc. has a market value of $1.9B and an enterprise value of $1.8B.

  • Shares outstanding: 106.8M.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • ADARx Pharmaceuticals, Inc. employs 100 people.

market figures as at 15 Oct 2026

Data provided by Twelve Data

Peers

ADRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ADRXADARx Pharmaceuticals, Inc.$1.9B
0
VERAVera Therapeutics, Inc.$1.9B
26
URGNUroGen Pharma Ltd.$1.9B
82
MLYSMineralys Therapeutics, Inc.$1.9B
18
PVLAPalvella Therapeutics, Inc.$1.8B
30
FTREFortrea Holdings, Inc.$2.0B
97
ZYMEZymeworks, Inc.$1.8B
59

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own ADARx Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ADRX news & analysis

ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares Granted in Its Initial Public Offering

GlobeNewsWire · 1 Oct 2026neutral

ADARx Pharmaceuticals announced the closing of the full exercise of the underwriters' option to purchase additional shares in connection with its initial public offering. This completes the additional share purchase granted in the IPO.

Why it matters — ADRX watchers would note this as a continuation of the company's IPO process, indicating the offering's additional shares have been fully exercised and closed.

FAQ

Frequently asked questions about ADRX stock

How does Ticker Nerd's model rank ADRX?

As at 13 Oct 2026, ADARx Pharmaceuticals, Inc. ranks 0 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (36 of 100).

What is the ADRX stock forecast for 2030?

No analyst covering ADARx Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ADRX are extrapolating price history, which says nothing about the business.

What does ADARx Pharmaceuticals, Inc. do?

ADARx Pharmaceuticals, Inc. is a late-stage biotechnology company focused on developing next-generation siRNA therapeutics.

What is the latest news on ADRX?

The most recent item we track (GlobeNewsWire, 1 Oct 2026): "ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares Granted in Its Initial Public Offering". ADARx Pharmaceuticals announced the closing of the full exercise of the underwriters' option to purchase additional shares in connection with its initial public offering. This completes the additional share purchase granted in the IPO.

Company

About ADARx Pharmaceuticals, Inc.

ADARx Pharmaceuticals, Inc. is a late-stage biotechnology company focused on developing next-generation siRNA therapeutics. The company works on RNA interference-based medicines designed to silence disease-causing genes and address conditions with significant unmet medical needs. Its current pipeline includes hepatic-targeted programs such as Agazisiran, a complement factor B program, Onvuzosiran for hereditary angioedema attack prevention, and ADX-626, a Factor XI program being studied for thrombotic disease and stroke prevention applications. ADARx Pharmaceuticals operates in the broader genetic medicine and precision therapeutics markets, where it aims to translate advanced oligonucleotide science into targeted treatments across multiple disease areas. Based in San Diego, California, the company is positioned as a clinical biotechnology developer with a focus on translational research and specialty drug development.

CEO Dr. Zhen Li Ph.D. · 100 employees · United States · https://www.adarx.com